The decrease in urinary IL-1β after empagliflozin treatment is in accordance with the results of the previous randomized, controlled study, which reported that empagliflozin inhibited the release of IL-1β from macrophage in T2DM patients with high cardiovascular risk33. This evidence concerns the gene IL1B and type 2 diabetes mellitus.